Welcome to our dedicated page for CHFS news (Ticker: CHFS), a resource for investors and traders seeking the latest updates and insights on CHFS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CHFS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CHFS's position in the market.
CHF Solutions, Inc. (NASDAQ:CHFS) announced a public offering of its common stock, intending to grant underwriters a 45-day option to purchase an additional 15% of the shares. The proceeds will support general corporate purposes, focusing on commercialization efforts. The offering is subject to market conditions, and there is uncertainty regarding the timing and size. Ladenburg Thalmann & Co. Inc. is the sole book-running manager, while Lake Street Capital Markets, LLC leads the offering.
CHF Solutions (Nasdaq: CHFS) has submitted a patent application for a new system aimed at enhancing peripheral venous access for Aquadex™ ultrafiltration and continuous renal replacement therapies. This innovation seeks to simplify the administration of these therapies, potentially improving patient outcomes by addressing fluid overload—a significant issue in critically ill patients. The Aquadex SmartFlow system currently facilitates ultrafiltration through both central and peripheral access, and this latest advancement is designed to make these therapies more accessible to healthcare providers.
CHF Solutions (Nasdaq: CHFS) announced the availability of its Aquadex SmartFlow® system to treat fluid overloaded pediatric patients at Puerto Rico Women and Children’s Hospital. The system's low extracorporeal volume of 35 ml is vital for delicate pediatric treatments, distinguishing it from other therapies. The company aims to improve outcomes for patients globally, with this expansion seen as a significant milestone. The Aquadex system is indicated for use in patients not responding to conventional medical management, underscoring the company's commitment to effective fluid management solutions.
CHF Solutions, Inc. (NASDAQ: CHFS) announced an equity award as a material inducement for a new hire, approved by independent directors on February 17, 2021. The individual received an option to purchase 300 shares of common stock at an exercise price of $9.46 per share, the closing price on the grant date. The option has a ten-year term and will vest over four years. CHF Solutions focuses on developing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy, aimed at patients suffering from fluid overload.
CHF Solutions (Nasdaq: CHFS) will participate in the ERAS Cardiac Society Virtual Conference on March 5-6, 2021. Dr. Daniel Beckles will present a lecture on managing fluid overload using Aquadex ultrafiltration therapy, focusing on cardiac surgery patients. This therapy addresses morbidity and mortality linked to fluid overload. CHF Solutions will also host a virtual booth for inquiries about the Aquadex SmartFlow system. President Nestor Jaramillo emphasizes the importance of educating providers to ensure optimal patient outcomes in cardiology.
CHF Solutions, Inc. (Nasdaq: CHFS) reported a strong fourth quarter for 2020 with a revenue increase of 49.5% to $2 million compared to the previous year. Gross margin rose to 56.1%, up from 50.8% in 2019, driven by higher utilization of the Aquadex System during the COVID-19 pandemic.
Operating expenses increased by 5.7% to $5.4 million, while net loss improved to $3.1 million from $4.4 million a year prior. The company ended the year with $14.4 million in cash and no debt.
CHF Solutions, Inc. (NASDAQ: CHFS) will release its fourth quarter 2020 financial results on March 2, 2021. A conference call and webcast will be held at 9:00 AM ET to discuss these results and provide a business overview. Investors can access the live webcast through the company's Investors page or by calling directly using provided numbers. CHF Solutions focuses on developing the Aquadex SmartFlow™ system for ultrafiltration therapy for patients with fluid overload, operating globally with subsidiaries in Australia and Ireland.
CHF Solutions (Nasdaq: CHFS) announced a patent application to enhance monitoring with its Aquadex SmartFlow™ system, aiming to improve patient outcomes by providing clinicians with more detailed output data. This new non-invasive technology will deliver timely cardiovascular parameters crucial for hemodynamic stability. President Nestor Jaramillo, Jr. emphasized the company's commitment to technological advancements that assist clinicians in optimizing ultrafiltration therapy. Fluid overload significantly affects critically ill patients, leading to extended hospital stays and readmissions.
CHF Solutions (Nasdaq: CHFS) has reported significant findings from a recent webinar discussing the ultrafiltration (UF) technique for managing heart failure. The retrospective study of 335 patients using the Aquadex FlexFlow® System showed favorable outcomes, including reduced rehospitalizations and improved renal function. Key observations indicated that Aquadex therapy can effectively decongest without harming renal health, allowing for reduced diuretic use post-treatment. The webinar highlighted early UF application's impact on patient outcomes and quality of life.
CHF Solutions (Nasdaq: CHFS) will host a physician-led webinar on January 27, 2021, discussing ultrafiltration for heart failure management. Key panelists from Abington Jefferson Health will share insights from their recent study published in the Journal of Cardiac Failure, highlighting the effectiveness of the Aquadex system in treating fluid overload. The system has shown promising results in reducing rehospitalizations and improving renal function. Registration for the event is available online, with an archived version to follow for those unable to attend.
